Jeevan Scientific Peer Comparison

BSE: 538837

₹80.00

₹2.97 (3.86%)

As on 24-Sep-2026 09:27IST

Market cap

₹155 Cr

Revenue (TTM)

₹71 Cr

P/E Ratio

44.4

P/B Ratio

2.1

Div. Yield

0 %

Edit

	Jeevan Scientific	Anthem Biosciences	Dr. Agarwal's Health Care	Dr. Lal Pathlabs	Genesis IBRC India	Global Health	Krishna Institute	Rainbow Children's	Vijaya Diagno	Vimta Labs
Market cap (₹ Cr)	155	49,700	15,713	32,271	189	40,209	33,529	14,288	16,149	2,725
Revenue (₹ Cr)	71	2,002	2,207	2,891	--	4,683	4,213	1,820	857	419
Net Profit (₹ Cr)	5.14	575.95	185.10	546.30	-0.86	552.34	190.80	290.28	187.49	79.66
Net Margin (%)	7.16	26.66	8.25	18.23	-2,391.67	11.55	4.49	15.63	21.32	18.53
RoE (%)	5.85	20.48	7.47	23.03	-3.56	14.93	9.45	18.11	20.58	18.52
Price to Earnings	44.36	86.29	105.91	59.55	--	72.30	164.12	50.07	86.13	34.21
Price-To-Book	2.12	15.88	7.60	12.35	4.75	9.78	8.86	8.37	16.03	5.79

Income Statement (₹ Cr)

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Operating Revenue	71.02	418.80	0.00	2,002.34	4,683.37
Total Income	71.83	429.85	0.04	2,160.20	4,783.78
Total Expenditure	56.46	273.66	0.87	1,209.46	3,704.62
EBITDA	14.55	145.14	-0.87	792.89	978.75
Depreciation	6.61	46.46	0.02	137.61	246.41
EBIT	7.95	98.68	-0.90	655.28	732.34
Interest	1.94	1.09	0.00	6.17	92.01
Other Income	0.81	11.05	0.04	157.86	100.41
Exceptional Items	0.00	-1.62	0.00	-24.39	-20.61
Profit before Tax	6.82	107.03	-0.86	782.58	720.14
Provision for Tax	1.68	27.37	0.00	206.63	167.80
Profit after Tax	5.14	79.66	-0.86	575.95	552.34

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Shareholder's Funds	71.94	456.87	40.07	3,042.52	3,961.57
Minority Interest	-1.63	0.00	0.00	0.00	3.84
Non-Current Liabilities	13.74	39.83	0.00	61.06	1,293.60
Current Liabilities	19.89	65.52	5.24	325.71	627.13
Total Liabilities	78.29	466.53	8.84	2,966.58	4,766.23

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Non-Current Assets	40.19	329.41	0.00	1,421.55	3,128.95
Current Assets	49.87	224.87	45.31	1,803.15	1,674.92
Total Assets	78.29	466.53	8.84	2,966.58	4,766.23
Total Debt*	15.14	8.52	0.00	108.96	327.88
Net Current Assets	29.98	159.35	40.07	1,477.43	1,047.79
Contingent Liabilities	--	2.74	--	54.44	88.77

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Cash From Operating Activities	10.07	94.05	0.00	270.55	623.76
Cash Flow from Investing Activities	-15.62	-75.54	--	-146.56	-720.94
Cash from Financing Activities	5.24	-16.12	--	-135.65	-97.23
Net Cash Inflow / Outflow	-0.30	2.40	0.00	-11.66	-194.41

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
ROCE (%)	3.17	25.23	51.69	28.55	20.50
ROE (%)	5.85	18.52	-3.56	20.48	14.93
ROA (%)	5.56	15.49	-3.18	33.59	10.35
EBIT Margin (%)	11.19	23.56	--	32.73	15.64
Net Margin (%)	7.16	18.53	-2,391.67	26.66	11.55
Cash Profit Margin (%)	0.00	0.00	--	0.00	0.00

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Revenue Growth (%)	61.33	14.22	--	-2.14	21.27
EBIT Growth (%)	393.61	6.64	-382.26	1.71	0.94
Net Profit Growth (%)	330.83	11.04	-124.73	14.12	3.43
EPS Growth (%)	235.44	-35.38	-119.33	17.10	2.70
Book Value Growth (%)	1.09	21.06	69.71	23.43	16.71

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Price / Earnings	40.05	33.64	-80.78	83.54	70.21
Price / Book Value	2.12	5.79	4.75	15.88	9.78
Dividend Yield (%)	0.00	0.33	0.00	0.23	0.03
EV/EBITDA	11.65	18.34	-216.46	61.56	40.57
Market Cap (₹ Cr)	63.50	2,223.71	--	0.00	32,181.74

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Debt to Equity	0.14	0.00	0.00	0.01	0.15
Short term debt to equity ratio	0.02	--	--	0.02	--
Current Ratio	2.51	3.43	8.64	5.54	2.67
Quick Ratio	2.35	2.97	8.64	5.15	2.54
Interest Coverage	4.51	99.28	--	127.84	8.83

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Debtors to sales (%)	29.14	25.24	--	29.49	8.78
Asset Turnover	0.77	0.81	0.00	1.17	0.88
Receivable days	110.00	102.52	--	92.78	25.07
Inventory Days	10.55	26.39	--	54.41	6.62
Payable days	255.53	--	--	51.72	79.17
Cash Conversion Cycle	-134.98	--	--	95.47	-47.48

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.